Please contact our sales representative to learn more information about this reagents.
Background
Solitomab (INN, development code MT110) is an artificial bispecific monoclonal antibody that is being investigated as an anti-cancer drug. It is a fusion protein consisting of two single-chain variable fragments (scFvs) of different antibodies on a single peptide chain of about 55 kilodaltons.